

Aegerion Pharmaceuticals 2019 Methodology Document - ABPI Disclosure Reporting

| | |
|--|--|
| Tax/VAT considerations: | Yearly amounts for each reportable HCP/HCO excluded VAT |
| Currency Aspects (including conversion rates): | All reported amounts are in British pounds. If the payment was made in another currency, the Company used the amount converted in British Pounds on the date of the invoice. |
| Cross Border Payments: | The Company searched for identified payments made to UK HCPs/HCOs from the US-based parent company (Aegerion, Inc.) or any of the Company's subsidiaries including Aegerion's UK- based subsidiary (Aegerion Ltd). |
| Multi-year contracts: | The Company reported all payments made to the reported HCPs/HCOs in calendar year 2019. If a contract contemplated payments to be made in subsequent calendar years, those payments will be reflected in those subsequent calendar years' filings. |
| Over-the-counter transfers of value: | N/A |
| Consent: | The contracts for the reported HCPs/HCOs included consent language between the Company and the reported HCP/HCO. The Company did require consent to be obtained in a stand-alone document. |
| Additional notes: | During the course of preparing our disclosure report, we became aware of a meal from January 2019 between our UK distributor and sub-contracted nurses. We do not have any additional details or supporting documentation for the meal/payment due to employee turnover, therefore, we were not able to determine if there were any potentially reportable transfers of value. However, we have addressed the gap in our data collection processes and are working to confirm that we do not miss any potentially reportable data in future reporting periods. |